44 2033180199
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Current Research: Integrative Medicine

Sign up for email alert when new content gets added: Sign up

Different hematopoiesis and response to 5-azacytidine treatment in Tp53 mutation mice

5th International Meeting on Complementary and Alternative Medicine & Therapies

September 18-19, 2017 Charlotte, USA

Tuoen Liu

West Virginian School of Osteopathic Medicine, USA

Posters & Accepted Abstracts: Curr Res Integr Med

Abstract :

TP53 R172H missense mutation and deletion are highly occurred in patients with myelodysplastic syndrome (MDS), the most common adult myeloid malignancy. In order to study the role of TP53 mutation in hematological system, we used four mouse models carrying Tp53 mutation including Tp53 R172H missense mutation (R172H/WT and R172H/R172H) and Tp53 deletion mice (Tp53+/- and Tp53-/-). We characterized the hematopoiesis and studied the blood chimerism after 5ΓΆΒ?Β?-Azacytidine (AZA) treatment in these mouse models. Tp53 R172H missense mutation mice have a minor reduction in myeloid-erythroid progenitors (MEP) compared to wide type (WT) mice. Tp53+/- and Tp53-/- mice have a higher percentage of hematopoietic stem cells (HSC) and lineage-/Sca+/Kit+ bone marrow (BM) progenitor cells (KLS) compared to WT mice. Competitive BM repopulation transplant studies showed that stem cells from all four Tp53 mutation mouse models have a competitive advantage over WT competitor stem cells, with Tp53-/- stem cells having the largest advantage based on peripheral blood chimerism. BM cells from donor (CD45.2 Tp53 mutation mice) and competitor (CD45.1 WT mice) were mixed and competitive repopulation assays were performed followed by AZA treatment. The Tp53-/- mice have a competitive disadvantage after AZA treatment compared to PBS treatment, in which inhibition of T cell development and maturation mostly contributes to the phenotype observed. Our studies showed that Tp53 mutation affects hematopoiesis in mice. Inhibition of T cell development and maturation by AZA may be a mechanism for the effectiveness of AZA in treating MDS patients carrying Tp53 deletion.

 
Google Scholar citation report
Citations : 67

Current Research: Integrative Medicine received 67 citations as per Google Scholar report

Current Research: Integrative Medicine peer review process verified at publons
pulsus-health-tech
Top